Form D · Other Technology

Indapta Therapeutics Inc.

Houston, TX · CIK 0001910175

Offering snapshot reported Oct 14, 2025 · SEC filing

Reported sold
$50.8M
Offering amount: $51.6M
Investors reported
46
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Sep 24, 2025
As reported in this filing

What changed?

Latest filing versus its linked predecessor, where available.

No comparable changes in the displayed metrics.

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Oct 14, 2025Initial$50,800,176No comparison46SEC filing
Feb 10, 2022Initial$33,603,097No comparison37SEC filing

Offering details

Securities
Equity, Other
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-560578
Total offering amount/sales amounts reflect (i) value of preferred stock issued upon conversion of outstanding notes; (ii) value of common stock issued in an exchange; and (iii) value of preferred stock issued in an exchange.
Includes preferred stock issued upon conversion of outstanding notes, common shares issued in exchange for preferred stock and preferred stock issued in exchange for common stock.

Source: Form D, filed Oct 14, 2025. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Guy Di Pierro Executive
Mark Frohlich Director, Executive
Lori Hu Director
Ronald Martell Director
Fabio Pucci Director
Laura Stoppel Director

Issuer details

Industry: Other Technology (See others in industry)

Address:
5000 Gulf Fwy. Building 4 Room 118
Houston, TX, 77023
Phone: 917-282-9768